Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time

Brain

Volumn 125, Issue 10, 2002, Pages 2202-2212

  Kuhlmann, Tanja ^a   Lingfeld, Gueanelle ^a   Bitsch, Andreas ^b   Schuchardt, Jana ^a   Brück, Wolfgang ^a,c,d  

^a HUMBOLDT UNIVERSITY   (Germany)

^b Ruppiner Kliniken GmbH   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

APP; Axon damage; Multiple sclerosis

Indexed keywords

AMYLOID PRECURSOR PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; AXONAL INJURY; CHRONIC DISEASE; CLINICAL FEATURE; CYTOTOXIC T LYMPHOCYTE; DEMYELINATION; DISEASE COURSE; FEMALE; GLIOSIS; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; INFLAMMATION; INFLAMMATORY CELL; MACROPHAGE; MALE; MICROGLIA; MULTIPLE SCLEROSIS; NERVE FIBER TRANSECTION; NEUROPROTECTION; PRIORITY JOURNAL; REMYELINIZATION;

EID: 0036788406     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/awf235     Document Type: Article

References (59)

1. Allen IV. Pathology of multiple sclerosis. In: Matthews WB, editor. McAlpine's multiple sclerosis. 2nd edn. Edinburgh: Churchill Livingstone; 1991. p. 341-78.
2. Allen IV, McKeown SR. A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis. J Neurol Sci 1979; 41: 81-91.
3. Arnold DL, Matthews PM, Francis G, Antel J. Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease. Magn Reson Med 1990; 14: 154-9.
4. Birken DL, Oldendorf WH. N-acetyl-L-aspartic acid: a literature review of a compound prominent in 1H-NMR spectroscopic studies of brain. [Review]. Neurosci Biobehav Rev 1989; 13: 23-31.
5. Bitsch A, da Costa C, Bunkowski S, Weber F, Rieckmann P, Brück W. Identification of macrophage populations expressing tumor necrosis factor-alpha mRNA in acute multiple sclerosis. Acta Neuropathol (Berl) 1998; 95: 373-7.
6. Bitsch A, Schuchardt J, Bunkowski S, Kuhlmann T, Brück W. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 2000; 123: 1174-83.
7. Bjartmar C, Kinkel PR, Kidd G, Rudick RA, Trapp BD. Axonal loss in normal-appearing white matter in a patient with acute MS. Neurology 2001; 57: 1248-52.
8. Bö L, Dawson TM, Wesselingh S, Mörk S, Choi S, Kong PN, et al. Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann Neurol 1994; 36: 778-86.
9. Bramlett HM, Kraydieh S, Green EJ, Dietrich WD. Temporal and regional patterns of axonal damage following traumatic brain injury: a beta-amyloid precursor protein immunocytochemical study in rats. J Neuropathol Exp Neurol 1997; 56: 1132-41.
10. Brück W, Porada P, Poser S, Rieckmann P, Hanefeld F, Kretzschmar HA, et al. Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol 1995; 38: 788-796.
11. Brück W, Bitsch A, Kolenda H, Brück Y, Stiefel M, Lassmann H. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 1997; 42: 783-93.
12. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernández O, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576-82.
13. Davie CA, Hawkins CP, Barker GJ, Brennan A, Tofts PS, Miller DH, et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994; 117: 49-58.
14. Davie CA, Barker GJ, Webb S, Tofts PS, Thompson AJ, Harding AE, et al. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain 1995; 118: 1583-92.
15. 1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis. J Neurol Neurosurg Psychiatry 1997; 63: 736-42.
16. Davie CA, Silver NC, Barker GJ, Tofts PS, Thompson AJ, McDonald WI, et al. Does the extent of axonal loss and demyelination from chronic lesions in multiple sclerosis correlate with the clinical subgroup? J Neurol Neurosurg Psychiatry 1999; 67: 710-5.
17. De Stefano N, Matthews PM, Antel JP, Preul M, Francis G, Arnold DL. Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol 1995; 38: 901-909.
18. De Stefano N, Matthews PM, Fu L, Narayanan S, Stanley J, Francis GS, et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 1998; 121: 1469-77.
19. De Stefano N, Narayanan S, Francis GS, Arnaoutelis R, Tartaglia MC, Antel JP, et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 2001; 58: 65-70.
20. Evangelou N, Konz D, Esiri MM, Smith S, Palace J, Matthews PM. Regional axonal loss in the corpus callosum correlates with cerebral white matter lesion volume and distribution in multiple sclerosis. Brain 2000; 123: 1845-9.
21. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997; 120: 393-9.
22. Filippi M, Iannucci G, Tortorella C, Minicucci L, Horsfield MA, Colombo B, et al. Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI. Neurology 1999a; 52: 588-94.
23. Filippi M, Tortorella C, Bozzali M. Normal-appearing white matter changes in multiple sclerosis: the contribution of magnetic resonance techniques. [Review]. Mult Scler 1999b; 5: 273-82.
24. Fisher E, Rudick RA, Cutter G, Baier M, Miller D, Weinstock-Guttman B, et al. Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients. Mult Scler 2000; 6: 373-7.
25. Fu L, Matthews PM, De Stefano N, Worsley KJ, Narayanan S, Francis GS, et al. Imaging axonal damage of normal appearing white matter in multiple sclerosis. Brain 1998; 121: 103-13.
26. Gass A, Barker GJ, Kidd D, Thorpe JW, MacManus D, Brennan A, et al. Correlation of magnetization transfer ratio with clinical disability in multiple sclerosis. Ann Neurol 1994; 36: 62-7.
27. Gimsa U, Peter SV, Lehmann K, Bechmann I, Nitsch R. Axonal damage induced by invading T cells in organotypic central nervous system tissue in vitro: involvement of microglial cells. Brain Pathol 2000; 10: 365-77.
28. Grimaud J, Barker GJ, Wang L, Lai M, MacManus DG, Webb SL, et al. Correlation of magnetic resonance imaging parameters with clinical disability in multiple sclerosis: a preliminary study. J Neurol 1999; 246: 961-7.
29. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, et al. Intramuscular interferon beta-1b therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000; 343: 898-904.
30. Koeberle PD, Ball AK. Nitric oxide synthase inhibition delays axonal degeneration and promotes the survival of axotomized retinal ganglion cells. Exp Neurol 1999; 158: 366-81.
31. Kornek B, Storch MK, Weissert R, Wallstroem E, Stefferl A, Olsson T, et al. Multiple sclerosis and chronic autoimmune encephalomyelitis. A comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol 2000; 157: 267-76.
32. Lassmann H. Comparative neuropathology of chronic experimental allergic encephalomyelitis and multiple sclerosis. Berlin: Springer-Verlag; 1983.
33. Lassmann H. Pathology of multiple sclerosis. In: Compston A, Ebers G, Lassmann H, McDonald I, Matthews B, Wekerle H, editors. McAlpine's multiple sclerosis. 3rd edn. London: Churchill Livingstone; 1998. p. 323-58.
34. Li GL, Farooque M, Holtz A, Olsson Y. Changes of beta-amyloid precursor protein after compression trauma to the spinal cord: an experimental study in the rat using immunohistochemistry. J Neurotrauma 1995; 12: 269-77.
35. Lovas G, Szilágyi N, Majtenyi K, Palkovits M, Komoly S. Axonal changes in chronic demyelinated cervical spinal cord plaques. Brain 2000; 123: 308-17.
36. Matthews PM, Pioro E, Narayanan S, De Stefano N, Lu F, Francis G, et al. Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. Brain 1996; 119: 715-22.
37. Matthews PM, De Stefano N, Narayanan S, Francis GS, Wolinsky JS, Antel JP, et al. Putting magnetic resonance spectroscopy studies in context: axonal damage and disability in multiple sclerosis. Semin Neurol 1998; 18: 327-36.
38. McDonald WI, Compston A, Edan G, Goodkin D, Hartung H-P, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-7.
39. Mews I, Bergmann M, Bunkowski S, Gullotta F, Brück W. Oligodendrocyte and axon pathology in clinically silent multiple sclerosis lesions. Mult Scler 1998; 4: 55-62.
40. Paolillo A, Pozzilli C, Gasperini C, Giugni E, Mainero C, Giuliani S, et al. Brain atrophy in relapsing-remitting multiple sclerosis: relationship with 'black holes', disease duration and clinical disability. J Neurol Sci 2000; 174: 85-91.
41. Pelletier J, Suchet L, Witjas T, Habib M, Guttmann CR, Salamon G, et al. A longitudinal study of callosal atrophy and interhemispheric dysfunction in relapsing-remitting multiple sclerosis. Arch Neurol 2001; 58: 105-11.
42. Pesini P, Kopp J, Wong H, Walsh JH, Grant G, Hökfelt T. An immunohistochemical marker for Wallerian degeneration of fibers in the central and peripheral nervous system. Brain Res 1999; 828: 41-59.
43. Pierce JE, Trojanowski JQ, Graham DI, Smith DH, McIntosh TK. Immunohistochemical characterization of alterations in the distribution of amyloid precursor proteins and beta-amyloid peptide after experimental brain injury in the rat. J Neurosci 1996; 16: 1083-90.
44. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
45. Prineas JW. The neuropathology of multiple sclerosis. In: Vinken PJ, Bruyn GW, Klawans HL, editors. Handbook of clinical neurology, Vol. 47. Amsterdam: Elsevier Science; 1985. p. 213-57.
46. Rawes JA, Calabrese VP, Khan OA, De Vries GH. Antibodies to the axolemma-enriched fraction in the cerebrospinal fluid and serum of patients with multiple sclerosis and other neurological diseases. Mult Scler 1997; 3: 363-9.
47. Redford EJ, Kapoor R, Smith KJ. Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible. Brain 1997; 120: 2149-57.
48. Sadatipour BT, Greer JM, Pender MP. Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis. Ann Neurol 1998; 44: 980-3.
49. Schiepers C, Van Hecke P, Vandenberghe R, Van Oostende S, Dupont P, Demaerel P, et al. Positron emission tomography, magnetic resonance imaging and proton NMR spectroscopy of white matter in multiple sclerosis. Mult Scler 1997; 3: 8-17.
50. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS. Clinical results. Neurology 2001; 56: 1496-504.
51. Silber E, Sharief MK. Axonal degeneration in the pathogenesis of multiple sclerosis. [Review]. J Neurol Sci 1999; 170: 11-8.
52. Simmons ML, Frondoza CG, Coyle JT. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 1991; 45: 37-45.
53. Smith KJ, Kapoor R, Hall SM, Davies M. Electrically active axons degenerate when exposed to nitric oxide. Ann Neurol 2001; 49: 470-6.
54. Thompson AJ, Montalban X, Barkhof F, Brochet B, Filippi M, Miller DH, et al. Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol 2000; 47: 831-5.
55. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-85.
56. van Waesberghe JH, Kamphorst W, De Groot CJ, van Walderveen MA, Castelijns JA, Ravid R, et al. Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol 1999; 46: 747-54.
57. van Walderveen MA, Kamphorst W, Scheltens P, van Waesberghe JH, Ravid R, Valk J, et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 1998; 50: 1282-8.
58. van Walderveen MA, Lycklama á Nijeholt GJ, Ader HJ, Jongen PJ, Polman CH, Castelijns JA, et al. Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging. Relation to clinical characteristics in subgroups of patients with multiple sclerosis. Arch Neurol 2001; 58: 76-81.
59. Yam PS, Takasago T, Dewar D, Graham DI, McCulloch J. Amyloid precursor protein accumulates in white matter at the margin of a focal ischaemic lesion. Brain Res 1997; 760: 150-7.